18 Facts About AstraZeneca


In 1999, AstraZeneca identified a new location for the company's US base, the "Fairfax-plus" site in North Wilmington, Delaware.

FactSnippet No. 439,641

In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology for £702 million.

FactSnippet No. 439,642

In 2010, AstraZeneca acquired Novexel Corp, an antibiotics discovery company formed in 2004 as a spin-off of the Sanofi-Aventis anti-infectives division.

FactSnippet No. 439,643

In 2011, AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business.

FactSnippet No. 439,644

In October 2013, AstraZeneca announced it would acquire biotech oncology company Spirogen for around US$440 million.

FactSnippet No. 439,645

On 19 May 2014 AstraZeneca rejected a "final offer" from Pfizer of £55 per share, which valued the company at £69.

FactSnippet No. 439,646

In February 2018, AstraZeneca announced it was spinning off six early-stage experimental drugs into a new biotechnology company, known as Viela Bio, valued at US$250 million.

FactSnippet No. 439,647

In October 2019, AstraZeneca announced it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as US$276 million.

FactSnippet No. 439,648

In February 2020, AstraZeneca agreed to sublicense its global rights to the drug Movantik, to Redhill Biopharma.

FactSnippet No. 439,649

In June 2020, AstraZeneca made a preliminary approach to Gilead Sciences about a potential merger, worth almost US$240 billion.

FactSnippet No. 439,650

In January 2021, India approved the use of the Oxford–AstraZeneca vaccine, paving the way for a mass immunisation campaign in the world's second most populous country.

FactSnippet No. 439,651

In September 2021, the lawsuit was finally settled with AstraZeneca agreeing to deliver 60 million doses of vaccines to EU member states by October, 75 million by the end of the year, and 65 million more by April 2022.

FactSnippet No. 439,652

In February 2016, AstraZeneca announced that a clinical trial of tremelimumab as a treatment for mesothelioma failed to meet its primary endpoint.

FactSnippet No. 439,653

In March 2011, AstraZeneca settled a lawsuit in the United States totalling US$68.

FactSnippet No. 439,654

When it is manufactured the result is a mixture of two mirror-imaged molecules, R and S Two years before the omeprazole patent expired, AstraZeneca patented S-omeprazole in pure form, pointing out that since some people metabolise R-omeprazole slowly, pure S-omeprazole treatment would give higher dose efficiency and less variation between individuals.

FactSnippet No. 439,655

In 2007, Marcia Angell, former editor-in-chief of the New England Journal of Medicine and a lecturer in social medicine at the Harvard Medical School, said in Stern, a German-language weekly newsmagazine, that AstraZeneca's scientists had misrepresented their research on the drug's efficiency, saying: "Instead of using presumably comparable doses [of each drug], the company's scientists used Nexium in higher dosages.

FactSnippet No. 439,656

However, the contract that AstraZeneca reached with the UK was very similar to that it reached with the EU, and it contained the phrase "best reasonable efforts"; the UK contract was signed on 28 August 2020, a day after the contract with the EU.

FactSnippet No. 439,657

The key difference seems to be that AstraZeneca entered into a preliminary agreement with the U K back in May 2020 which arranged for "the development of a dedicated supply chain for the U K " The failure to produce the vaccine in the anticipated quantities contributed to the low vaccination rates of vulnerable populations of the European Union at the beginning of the outbreak of more virulent variants of SARS-CoV-2 in early 2021.

FactSnippet No. 439,658